Trial Profile
Nimotuzumab safety and effectiveness in inoperable esophageal tumors of epithelial origin. Phase IV
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 14 Oct 2020
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary)
- Indications Oesophageal cancer
- Focus Adverse reactions
- 05 Oct 2020 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2016 New trial record